News & Media

Admedus 2017 Annual General Meeting webinar

17, November, 2017

Posted In: Featured, In the media

The investor webinar from our AGM on 16 November 2017 is now available to view via this link – AHZ – AGM 16 November 2017

> Read more

Admedus announces facility agreement with Partners for Growth

26, October, 2017

Posted In: Featured, In the media

Admedus Ltd today announced that it has entered into an agreement with Partners for Growth (PFG) for a secured debt facility of up to AUD $10 million. Based in the San Francisco Bay area, PFG is a partnership that provides capital funding debt solutions to private and public technology and life science companies. Read full […]

> Read more

Admedus TAVR project on track with new IP applications

24, October, 2017

Posted In: Featured, In the media, Blog

Admedus Ltd today announced that it has submitted IP applications relating to the development of a new Transcatheter Aortic Valve Replacement (TAVR) device. Read the full ASX statement here.

> Read more

New neck and head cancer treatment a step closer to trials

23, October, 2017

Posted In: Featured, In the media

As reported widely across Australian media outlets, Admedus Immunotherapies recently received a $250,000 Government grant from the Advance Queensland Ignite Ideas Fund to support human clinical trials, led by Professor Ian Frazer, of a new vaccine that could be used to treat head and neck cancer. Find a copy of the story on News.com,  7 News  or Brisbane Times. Read the full […]

> Read more

Notice of 2017 Annual General Meeting

13, October, 2017

Posted In: Blog

Admedus is pleased to announce the Annual General Meeting will be held at 11.00am (AEST) on 16 November 2017, at the Novotel Hotel in Brisbane, Australia.

> Read more

Update on experts’ meeting (advisory board)

13, October, 2017

Posted In: Featured

Recently, at the Admedus advisory board meeting run consecutively with the EACTS annual congress in Vienna, doctors validated the clinical benefits/medical utility and value to patients of our single piece aortic valve (vs. three piece leaflet from the competitors) in both the TAVR and SAVR settings. Our development work in this area continues as we […]

> Read more

Investor webinar 5 September 2017

1, September, 2017

Posted In: Featured, In the media, Videos, Blog

Admedus Limited (ASX: AHZ) held an investor webinar on 5 September, 2017 to discuss the results of the Company’s Preliminary Final Report (Appendix 4E) for the year ended 30 June 2017.  Admedus CEO Wayne Paterson will provide a review of the Company’s year-end performance as well as operational and business highlights.

> Read more

Admedus announces exclusive supply agreement with 4C Medical

Admedus announces exclusive supply agreement with 4C Medical

31, August, 2017

Posted In: In the media, Blog

Admedus Limited is pleased to announce that it has entered an exclusive supply agreement with 4C Medical Technologies, Inc. (4C Medical), a Minnesota-based developer of minimally invasive therapies for structural heart disease. Read more here.

> Read more

Admedus beats revenue forecasts for financial year 2017

31, August, 2017

Posted In: Featured, In the media

Admedus has delivered a full year sales increase of 58% to $22.3 million for financial year 2017, compared to the previous financial year. Read more here.

> Read more

Sponsorship supports kids with heart disease

15, August, 2017

Posted In: Featured, In the media

Admedus Ltd is proud to announce a six-month $20k sponsorship of the HeartKids Education Program which provides vital resources for families of children living with congenital/childhood heart disease. In Australia, congenital/childhood heart disease is the leading cause of death for children under a year old and nearly three thousand babies are born with a heart […]

> Read more